News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Santhera Pharmaceuticals AG Eyes Approval of Lead Drug, Catena in First Half of 2011
June 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss Santhera is aiming to seek approval for lead drug Catena to treat a rare eye disease in the first half of 2011 after a trial showed it improved sight, boosting the biotech group's prospects.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Tariffs
Trump Delays Pharma Tariffs Yet Again
October 2, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
October 1, 2025
·
2 min read
·
Dan Samorodnitsky
Complete response letters
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease
October 1, 2025
·
2 min read
·
Tristan Manalac
Government
US Government Shuts Down, FDA Closed for New Applications
October 1, 2025
·
4 min read
·
Annalee Armstrong
